Higher proportions of HER2-low recurrent tumours than primary tumours were observed in both groups: 50.1% for distant metastases versus 45.8% in the corresponding primary tumours, and 49.7% versus 42.8% for local recurrences. The gene discussed is ERBB2; the disease is neoplasm.